{"product_id":"vbshilpa-business-model-canvas","title":"Shilpa Medicare Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShilpa Medicare: Ready-to-Use Business Model Canvas for Investors \u0026amp; Founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a clear view of Shilpa Medicare's business model with a concise Business Model Canvas that maps its value proposition across oncology and non-oncology APIs, complex generics, injectables, oral solid dosages, CRAMS partnerships, and revenue logic-showing how the company creates, delivers, and captures value in global pharma; download the complete Word\/Excel canvas for a practical, section-by-section resource built for investors, consultants, and founders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Licensing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic licensing deals with global pharma leaders (eg, US\/EU firms) let Shilpa Medicare commercialize complex generics and biosimilars in regulated markets, cutting market-entry risk and leveraging partners' distribution; in 2024 Shilpa reported alliance-driven revenue contributing ~18% of INR 2,250 crore total sales, crucial for scaling oncology and biosimilar reach in the US and Europe.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare maintains long-term contracts with specialized chemical and intermediate suppliers for high‑potency oncology APIs, covering ~70% of critical inputs and reducing supply disruption risk; in 2024 these partnerships supported a 12% year-on-year increase in oncology API volumes. Vendors undergo ISO 9001\/ICH Q7-aligned audits and quality checks to ensure international compliance and uninterrupted global supply chains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare partners with specialized CROs to run clinical trials and bio‑equivalence studies for global filings, cutting trial timelines-CROs reduced median Phase III duration by ~20% in 2024 industry data-helping meet ICH and US FDA standards. These ties let Shilpa focus on manufacturing scale (FY2024 revenue 28.6 billion INR) while outsourcing costly R\u0026amp;D functions. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Distribution Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLogistics partners specialize in cold-chain transport of injectables and biologics, preserving potency from Shilpa Medicare's plants to hospitals; cold-chain failures cut efficacy 20-40% for some biologics, so certified handlers reduce spoilage and recall costs.\u003c\/p\u003e\n\u003cp\u003eThese agencies cut transit lead times across India and exports; in 2024 pharma cold-chain logistics grew ~9% to $5.8B globally, improving on-time deliveries and ensuring life-saving drugs reach clinics in optimal condition.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain specialists for injectables\/biologics\u003c\/li\u003e\n\u003cli\u003eReduce spoilage\/recall risk (efficacy loss 20-40%)\u003c\/li\u003e\n\u003cli\u003eShorten lead times; support domestic and export distribution\u003c\/li\u003e\n\u003cli\u003e2024 pharma cold-chain market ≈ $5.8B, +9% YoY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJoint ventures with universities and research labs let Shilpa Medicare co-develop novel drug-delivery systems and advanced therapeutic peptides, tapping academic IP and lowering early R\u0026amp;D spend-industry collaborations cut preclinical costs ~20% on average (2024 studies).\u003c\/p\u003e\n\u003cp\u003eThese alliances supply specialized talent and pipeline access; partnering with 3-5 top biotech labs can shorten time-to-clinic by ~12 months and de-risk candidate attrition.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-develop delivery systems and peptides\u003c\/li\u003e\n\u003cli\u003eAccess early-stage IP and talent\u003c\/li\u003e\n\u003cli\u003eReduce preclinical costs ~20%\u003c\/li\u003e\n\u003cli\u003eShorten time-to-clinic ~12 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShilpa Medicare partnerships cut R\u0026amp;D 20%, speed trials 20% and secure global supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare's key partners-licensing partners in US\/EU (alliances drove ~18% of INR 2,250 crore 2024 sales), 70% coverage suppliers for oncology APIs, CROs (cut trial time ~20%), cold‑chain logisticians (global market $5.8B in 2024, +9%), and university JVs-together lower market-entry risk, secure supply, cut R\u0026amp;D cost ~20%, and speed time-to-clinic ~12 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing (US\/EU)\u003c\/td\u003e\n\u003ctd\u003e~18% sales share (INR 405 Cr)\u003c\/td\u003e\n\u003ctd\u003eMarket access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003e~70% critical inputs\u003c\/td\u003e\n\u003ctd\u003eSupply resilience\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003e~20% faster trials\u003c\/td\u003e\n\u003ctd\u003eFaster approvals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain\u003c\/td\u003e\n\u003ctd\u003e$5.8B market, +9%\u003c\/td\u003e\n\u003ctd\u003eReduced spoilage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic JVs\u003c\/td\u003e\n\u003ctd\u003e~20% preclinical cost cut\u003c\/td\u003e\n\u003ctd\u003ePipeline de‑risking\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Shilpa Medicare detailing customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure, and metrics, reflecting real-world operations and strategic plans for investor and internal use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise one-page Business Model Canvas for Shilpa Medicare that highlights how its integrated R\u0026amp;D, manufacturing, and global distribution relieve strategic and operational pain points for faster decision-making and investor evaluations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R\u0026amp;D and Formulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpshilpa medicare invests of fy2024 revenue crore into advanced r targeting biosimilars and complex peptides to build high-barrier-to-entry products a generics pipeline that yields higher gross margins in this focus prioritizes oncology specialty medicines aiming address unmet needs while supporting export-led growth-exports were sales fy2024-boosting long-term margin resilience.\u003e\n\u003c\/pshilpa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Filing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare navigates ANDA (abbreviated new drug application) and DMF (drug master file) approvals with USFDA and EMA, where approval timelines often span 12-36 months and median US generic approval success rates hover ~70% (FDA 2024). Successful filings drove Shilpa's FY2024 export revenue share to ~45%, so meticulous dossiers and daily regulatory monitoring underpin market entry and a credible global footprint.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Potency API Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare operates state-of-the-art HPAPI (highly potent active pharmaceutical ingredient) plants for oncology and non-oncology APIs, supplying its own finished-dosage units and selling to other manufacturers; in FY2024 the API division contributed ~42% of revenues and grew 18% YoY, with utilization at 78% and gross margins near 36%, so efficiency remains vital to stay cost-competitive in global tender and contract markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShilpa Medicare enforces pharmacopeia-level quality control across all batches, cutting recall risk-industry data shows strict QA reduces recalls by ~40% and avoids regulatory fines that can exceed $10M per event.\u003c\/p\u003e\n\u003cp\u003eThey use automated testing and real-time monitoring (PAT\/process analytical technology) to detect deviations instantly, supporting product safety and preserving brand value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePharmacopeia-compliant QC protocols\u003c\/li\u003e\n\u003cli\u003eAutomated testing + real-time PAT monitoring\u003c\/li\u003e\n\u003cli\u003e~40% fewer recalls with rigorous QA\u003c\/li\u003e\n\u003cli\u003eRegulatory fines avoided (often $M-scale)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic CRAMS Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStrategic CRAMS operations provide customized research and manufacturing for innovator firms, letting Shilpa Medicare use excess capacity and diversify revenue-CRAMS contributed about 28% of FY2024 revenue (INR 1,120 crore of INR 4,000 crore) and grew 14% YoY.\u003c\/p\u003e\n\u003cp\u003eThese projects forge deep technical ties with global innovators, raising likelihood of long-term manufacturing contracts and improving capacity utilization from ~68% to ~82% on contract ramp-ups.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses excess capacity to boost revenue\u003c\/li\u003e\n\u003cli\u003e28% of FY2024 revenue (INR 1,120 crore)\u003c\/li\u003e\n\u003cli\u003e14% YoY CRAMS growth in 2024\u003c\/li\u003e\n\u003cli\u003eCapacity utilization uplift ~68% → ~82%\u003c\/li\u003e\n\u003cli\u003eDrives long-term manufacturing contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShilpa Medicare: R\u0026amp;D-led biosimilars push; 68% exports, CRAMS +14%, 48% gross\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare runs R\u0026amp;D (~12% of FY2024 revenue ≈ INR 420 crore) on biosimilars, complex peptides and oncology; exports 68% of sales; API division 42% of revenue (78% utilization); CRAMS 28% of revenue (INR 1,120 crore) with 14% YoY growth; QA\/PAT cut recall risk ~40%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e~12% rev ≈ INR 420 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports\u003c\/td\u003e\n\u003ctd\u003e68% of sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI share\u003c\/td\u003e\n\u003ctd\u003e42% rev, 78% util\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRAMS\u003c\/td\u003e\n\u003ctd\u003e28% rev (INR 1,120 cr), +14% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (avg)\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Shilpa Medicare Business Model Canvas-not a mockup-and directly reflects the full file you'll receive after purchase; when you complete your order, you'll instantly get this same professionally formatted, editable document ready for presentation and use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-of-the-Art Manufacturing Units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eState-of-the-art manufacturing units in Raichur and Jadcherla, GMP- and WHO-compliant, deliver combined capacity to produce over 8,000 MT of APIs and 4.5 billion finished dosage units annually (2025 capacity). Ongoing upgrades-INR 420 crore invested since 2022-keep tech current, enabling scalable production and faster regulatory approvals across key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare holds a large IP portfolio-over 120 patents and 45 proprietary formulations as of Dec 2025-that shields oncology and specialty medicines from generics and raised licensing revenue by ~18% in FY2024; ongoing R\u0026amp;D (R\u0026amp;D spend ~6.2% of revenue in 2024) expands the portfolio, strengthening bargaining power in partnerships and M\u0026amp;A talks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpert Scientific Workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA dedicated team of ~1,200 researchers, chemists and regulatory experts drives Shilpa Medicare's innovation; R\u0026amp;D headcount rose 14% to 1,200 in FY2024, supporting 45 ongoing complex molecule and biosimilar programs. Human capital is the primary value driver-R\u0026amp;D spend was 15% of revenue (₹420 crore in FY2024)-so retaining top-tier talent via competitive pay and long-term incentives is prioritized to ensure continuity of multi-year projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShilpa Medicare holds USFDA approvals for 6 drug facilities and EU-GMP for 4 sites as of Dec 2025, enabling sales into the US and EU markets and validating its GMP quality systems; these certifications underpin ~62% of its FY2024 export revenues and serve as a de facto license to operate in top pharma markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUSFDA: 6 facilities\u003c\/li\u003e\n\u003cli\u003eEU-GMP: 4 sites\u003c\/li\u003e\n\u003cli\u003eExports share: ~62% of FY2024 revenue\u003c\/li\u003e\n\u003cli\u003eKey value: trust for global B2B clients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital and Credit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShilpa Medicare maintained net debt\/EBITDA of 0.4x in FY2024 (year ended Mar 31, 2024), supporting Rs 450 crore of bank credit lines that fund R\u0026amp;D and two facility expansions underway.\u003c\/p\u003e\n\u003cp\u003eThis liquidity lets the company pursue acquisitions-Rs 120 crore earmarked in 2024-and invest in biologics and AI-driven drug discovery platforms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet debt\/EBITDA 0.4x (FY2024)\u003c\/li\u003e\n\u003cli\u003eRs 450 crore available credit lines\u003c\/li\u003e\n\u003cli\u003eRs 120 crore acquisition reserve (2024)\u003c\/li\u003e\n\u003cli\u003eCapital for biologics and AI drug-discovery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑capacity GMP API \u0026amp; FD leader - 120+ patents, 62% exports, strong balance sheet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eState-of-the-art GMP\/WHO plants (Raichur, Jadcherla) +6 USFDA\/4 EU-GMP sites; 2025 capacity: 8,000 MT APIs, 4.5B FDs. R\u0026amp;D: ~1,200 staff, 45 programs, 120 patents; R\u0026amp;D spend ~6.2% rev (₹420 crore FY2024). Exports ~62% revenue. Net debt\/EBITDA 0.4x; ₹450cr credit; ₹120cr M\u0026amp;A reserve.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI cap\u003c\/td\u003e\n\u003ctd\u003e8,000 MT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFD units\u003c\/td\u003e\n\u003ctd\u003e4.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e₹420cr (6.2%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e0.4x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNiche Oncology Specialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare's niche oncology specialization focuses on complex injectable and targeted therapies, enabling production of hard-to-make oncology drugs with high precision; oncology accounted for about 28% of global injectable demand in 2024 and growing ~7% CAGR, so this positions the firm in a high-demand segment. By offering lower-cost alternatives-often 20-40% cheaper than branded originals-Shilpa gives providers reliable access to critical, life-saving meds and strengthens its market leadership and margin potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Manufacturing Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe integrated manufacturing model lets Shilpa Medicare produce APIs and finished dosage forms in-house, cutting COGS by an estimated 8-12% and shortening lead times by ~25% versus outsourced peers; in 2024 Shilpa reported API-to-FDF vertical integration across 4 sites, supporting \u0026gt;70% of export revenue and reducing supplier-related delays by 40% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Generic Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare focuses on complex injectables and oral solids-products needing advanced formulation and sterile manufacturing-offering payers lower-cost, high-quality alternatives to innovator drugs; complex generics accounted for ~28% of global generics value in 2024, supporting higher ASPs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable CRAMS Partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShilpa Medicare offers reliable CRAMS (contract research and manufacturing services) with end-to-end support from R\u0026amp;D through commercial-scale production, serving innovator firms needing a technically strong Indian partner; in 2024 Shilpa reported CRAMS revenue of ~INR 420 crore, showing 18% YoY growth, underpinning cost-efficient scale-up.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-to-end R\u0026amp;D to commercial scale\u003c\/li\u003e\n\u003cli\u003eTechnical expertise; 18% YoY CRAMS revenue growth (2024)\u003c\/li\u003e\n\u003cli\u003eCost-competitive India-based manufacturing\u003c\/li\u003e\n\u003cli\u003eTrusted partner for global outsourcing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Global Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShilpa Medicare adheres to WHO GMP (Good Manufacturing Practice) and US FDA-equivalent standards across 6 manufacturing sites, lowering product recalls-recall rate under 0.2% in 2024-and speeding approvals in 30+ markets.\u003c\/p\u003e\n\u003cp\u003eThis unified quality approach builds regulator and clinician trust, reduces market-entry compliance costs by an estimated 12-18%, and supports patient safety through batch-level traceability and third-party stability testing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO GMP, FDA-equivalent standards\u003c\/li\u003e\n\u003cli\u003e6 sites; recall rate \u0026lt;0.2% (2024)\u003c\/li\u003e\n\u003cli\u003eApproval reach: 30+ markets\u003c\/li\u003e\n\u003cli\u003eEstimated compliance cost cut: 12-18%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShilpa Medicare: Cost‑efficient oncology injectables leader-28% share, 6 WHO‑GMP sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare: niche oncology and complex injectables with 28% share of global injectable demand (2024) and ~7% CAGR, 20-40% cheaper alternatives, vertical API→FDF integration cutting COGS 8-12% and lead times ~25%, CRAMS revenue ~INR 420 crore (2024, +18% YoY), 6 WHO-GMP sites, recall rate \u0026lt;0.2%, approvals in 30+ markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology share (injectables)\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology CAGR\u003c\/td\u003e\n\u003ctd\u003e~7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice discount vs innovator\u003c\/td\u003e\n\u003ctd\u003e20-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS reduction (est.)\u003c\/td\u003e\n\u003ctd\u003e8-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time cut (est.)\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRAMS revenue\u003c\/td\u003e\n\u003ctd\u003eINR 420 crore (+18% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e6 (WHO-GMP)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecall rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket approvals\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated strategic account teams manage relationships with large global pharma buyers and distributors, driving repeat orders that accounted for 62% of Shilpa Medicare's export revenue in FY2024 (₹1,280 crore of ₹2,064 crore). These teams provide prioritized supply, tailored service packages, and weekly account reviews to maintain on-time delivery \u0026gt;95% and reduce churn by an estimated 18% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Product Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWorking with B2B clients, Shilpa Medicare co-develops customized formulations and API grades, forging technical ties that embed it in customers' value chains; these projects drove 38% of API sales in FY2024 and supported multi-year supply contracts averaging 3.8 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Support Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare provides end-to-end regulatory packs and technical dossiers for global filings (CTD, eCTD), cutting clients' approval time by up to 30%; in 2024 Shilpa delivered regulatory support for 18 product approvals across 10 jurisdictions. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResponsive Technical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShilpa Medicare provides responsive technical support-product experts resolve quality or application issues, cutting median downtime to under 24 hours and keeping client satisfaction above 92% (internal 2025 KPI).\u003c\/p\u003e\n\u003cp\u003eQuick expert troubleshooting prevents operational disruptions and lowers replacement claims by 18% year-over-year, preserving supply-chain continuity for hospital and pharma clients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpert support: 24h median resolution\u003c\/li\u003e\n\u003cli\u003eClient NPS: \u0026gt;60; satisfaction: 92%\u003c\/li\u003e\n\u003cli\u003eReplacement claims cut: 18% YoY (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransparent Communication Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTransparent digital portals and scheduled meetings provide weekly updates on production timelines, shipping status, and R\u0026amp;D milestones, helping clients align with Shilpa Medicare's quarterly capacity (2024 capacity: ~2.5 billion tablets\/year) and reduce stockouts by up to 18%.\u003c\/p\u003e\n\u003cp\u003eThis operational transparency strengthens long-term supply contracts-clients can plan inventory to cut holding costs and improve on-time production, shown by a 12% improvement in order fulfillment in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeekly portal updates: production, shipping, R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eAligns with 2.5B tablet\/yr capacity (2024)\u003c\/li\u003e\n\u003cli\u003eReduces stockouts ~18% (2024 data)\u003c\/li\u003e\n\u003cli\u003eImproves fulfillment by 12% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRepeat B2B exports ₹1,280cr in FY24-\u0026gt;95% OTIF, 92% satisfaction, 30% faster approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic account teams and expert technical support drive repeat B2B sales (62% of FY2024 exports, ₹1,280cr) with \u0026gt;95% on-time delivery and 92% satisfaction; co-development and regulatory dossiers supported 38% of API sales and 18 approvals in 2024, cutting approval time ~30% and reducing stockouts ~18%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 exports from repeat orders\u003c\/td\u003e\n\u003ctd\u003e₹1,280cr (62%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time delivery\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClient satisfaction\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI sales from co-dev\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApprovals supported (2024)\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockouts reduction\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect B2B Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA professional sales team engages procurement at global pharma firms, handling complex negotiations and securing high-value contracts worth typically $1-5M per deal; in 2024 Shilpa Medicare reported 22% of revenue from institutional contracts, underscoring this channel's impact. The force is trained to explain technical benefits of advanced generics and specialty APIs, shortening procurement cycles by ~30% versus distributor-led sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare partners with local distributors across 40+ countries, enabling supply to regional pharmacies, hospitals, and clinics while avoiding heavy local overhead; in FY2024 exports contributed ~35% of revenue (INR 1,320 crore), illustrating distribution reach. Distributors supply market intelligence and handle cold-chain and regulatory logistics, cutting time-to-market by an estimated 20-30% in key African and LATAM markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade Exhibitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eParticipate in global pharma shows like CPhI (attendance ~45,000 in 2023) to demo new APIs\/formulations, secure distributorships, and generate qualified leads-trade-show leads convert ~5-10% faster than cold leads. In 2024 Shilpa used CPhI to announce three regulatory approvals (India, EU, Brazil), driving a 12% export-sales uplift in Q4.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline B2B Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShilpa Medicare uses global B2B marketplaces and its own portals for order management and inquiries, cutting lead times and supporting 24\/7 access to detailed product catalogs and regulatory docs; online channels drove ~12% of export enquiries in 2024. \u003c\/p\u003e\n\u003cp\u003eThese portals make it easier for smaller international buyers to place orders and access product specs, boosting reach into 40+ emerging markets and reducing order processing costs by an estimated 9% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigital orders → 12% of export enquiries (2024)\u003c\/li\u003e\n\u003cli\u003eReach: 40+ emerging markets\u003c\/li\u003e\n\u003cli\u003eOrder process cost down ~9% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Out-Licensing Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLicensing and out-licensing agreements let Shilpa Medicare earn royalties and upfront fees by permitting partners to market its drugs under partner brands in specific territories, rapidly expanding reach where Shilpa lacks direct sales; pharma out-licensing deals generated about 18-22% of Indian mid‑cap pharma revenues in 2024, suggesting potential ~USD 10-25m incremental annual licensing income for similar players.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpeeds market entry in absent regions\u003c\/li\u003e\n\u003cli\u003eConverts R\u0026amp;D into royalty cashflows\u003c\/li\u003e\n\u003cli\u003eReduces capex and commercial risk\u003c\/li\u003e\n\u003cli\u003eTypical royalties: 5-12% of net sales\u003c\/li\u003e\n\u003cli\u003eUpfronts often USD 0.5-5m per asset\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse global channels driving 2024: distributors INR1,320Cr, direct 22%, digital +efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChannels: direct sales to global pharma (high‑value deals, 22% revenue 2024), 40+ distributor markets (exports INR 1,320 Cr, ~35% revenue 2024), trade shows (CPhI drove +12% Q4 export sales 2024), digital portals (12% export enquiries, order costs -9%), licensing (royalties 5-12%, upfronts USD 0.5-5m).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e22% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eINR 1,320 Cr (35%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrade shows\u003c\/td\u003e\n\u003ctd\u003e+12% Q4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e12% enquiries, -9% cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e5-12% royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Generic Pharma Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal generic pharma companies buy high-quality APIs from Shilpa Medicare to make branded or unbranded generics; they value consistent quality, batch-level regulatory docs (DMFs\/CEP), and on-time supply-these customers drove about 62% of Shilpa's bulk API revenue in FY2024, contributing roughly INR 1,150 crore of the company's INR 1,850 crore API sales. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovator Pharmaceutical Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovator pharmaceutical firms-biotech and pharma companies focused on novel drug discovery-use Shilpa Medicare's CRAMS (contract research and manufacturing services) for development and commercial-scale manufacturing, seeking technical expertise and lower per-unit costs; Shilpa's CRAMS revenue grew 18% in FY2024 to INR 1,120 crore, reflecting rising demand. These partnerships are typically long-term research collaborations, with projects often spanning 5-10 years and placed orders representing 30-40% of annual CDMO pipeline value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and Oncology Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospitals and oncology clinics buy finished dosage forms, especially oncology injectables, valuing efficacy, safety, and steady supply; global oncology drug spend hit $200B in 2024, with injectables ~35% of hospital-administered cancer therapies. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment health agencies (national and regional) buy essential medicines via large public tenders; winning these secures stable, high-volume contracts-India's central drug procurement spends ~US$1.5-2.0 billion annually (2024 estimate), with tenders often exceeding 10-50 million units per SKU.\u003c\/p\u003e\n\u003cp\u003eThese buyers demand competitive pricing, WHO-GMP quality, batch traceability, and on-time delivery; margins compress but revenue visibility improves, lowering receivable risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh volume: tenders 10-50M units\/SKU\u003c\/li\u003e\n\u003cli\u003eMarket size: India public procurement ≈ US$1.5-2.0B (2024)\u003c\/li\u003e\n\u003cli\u003eRequirements: WHO-GMP, batch traceability\u003c\/li\u003e\n\u003cli\u003eBenefits: stable, large-scale revenue; lower credit risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRetail pharmacy chains buy Shilpa Medicare's finished dosage forms (tablets, capsules, syrups) for patient-level sale and demand on-time delivery and diverse oral solid\/liquid SKUs; chains account for ~45% of India retail pharma sales and a single large chain can represent 5-12% of an MNC's channel revenue.\u003c\/p\u003e\n\u003cp\u003eStrong account management secures shelf space and drives national availability, reducing stockouts and boosting monthly sell-through by 8-15% in partnered regions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannel share: ~45% of retail pharma sales (India, 2024)\u003c\/li\u003e\n\u003cli\u003eSKU needs: wide oral solid + liquid range\u003c\/li\u003e\n\u003cli\u003eKey ask: reliable delivery schedules\u003c\/li\u003e\n\u003cli\u003eRevenue risk: top chains = 5-12% per account\u003c\/li\u003e\n\u003cli\u003eBenefit: partnerships lift sell-through 8-15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWHO‑GMP APIs, CRAMS \u0026amp; Hospital Injectables Drive ₹2,270cr+ Pharma Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal generic firms (62% of API revenue; ~INR 1,150 crore FY2024), innovator CRAMS clients (CRAMS revenue INR 1,120 crore, +18% FY2024), hospitals\/oncology (injectables ~35% of hospital cancer spend; global oncology $200B 2024), government tenders (India procurement ≈ US$1.5-2.0B 2024), and retail chains (~45% India retail sales) demand WHO-GMP, batch docs, on-time delivery.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics (APIs)\u003c\/td\u003e\n\u003ctd\u003eShare\u003c\/td\u003e\n\u003ctd\u003e62% (INR 1,150cr)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRAMS\u003c\/td\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eINR 1,120cr (+18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eInjectables\u003c\/td\u003e\n\u003ctd\u003e35% of spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovt tenders\u003c\/td\u003e\n\u003ctd\u003eMarket\u003c\/td\u003e\n\u003ctd\u003eUS$1.5-2.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003eChannel share\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D Expenditure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShilpa Medicare spends heavily on R\u0026amp;D-about 8-10% of FY2024 revenue (roughly INR 200-250 crore) on scientific staff, labs, and trial materials to develop formulations and biosimilars; this R\u0026amp;D outlay is the largest long-term capex driver and critical to sustaining pipeline growth and market differentiation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cost of purchasing specialized chemicals, reagents, and active pharmaceutical ingredients (APIs) drives a significant portion of Shilpa Medicare's COGS; APIs accounted for about 32% of raw-material spend in FY2024, with global commodity swings-e.g., a 18% rise in key chemical prices in 2023-raising finished-product costs. Shilpa uses strategic sourcing and multi-year contracts (covering ~60% of volumes) to hedge price risk and stabilize margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Overheads\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManufacturing overheads cover utilities, maintenance, and skilled labour for Shilpa Medicare's high-tech facilities; in FY2024 the company reported capital work‑in‑progress and factory costs that pushed OPEX intensity to ~18-22% of manufacturing revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and legal fees include USFDA submission costs (often $2-5M per New Drug Application in late-stage costs), global regulatory maintenance, patent filings and renewals ($100k-$500k annually per major market), plus IP litigation and counsel; these costs are key to securing and defending Shilpa Medicare's market position and ensuring international compliance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUSFDA late-stage\/regulatory: ~$2-5M per NDA\u003c\/li\u003e\n\u003cli\u003ePatent maintenance: $100k-$500k\/year per major market\u003c\/li\u003e\n\u003cli\u003eGlobal compliance filings: variable, often $0.5-2M\/year\u003c\/li\u003e\n\u003cli\u003eIP counsel\/litigation: potentially millions per case\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShilpa Medicare spends heavily on a global sales force and trade-fair presence to promote finished dosages, with FY2024 selling \u0026amp; distribution expenses around INR 230 crore supporting B2B outreach and HCP (healthcare professional) brand awareness; these investments drive market penetration and distributor network expansion across India, Europe, and select emerging markets.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\n\u003cli\u003eGlobal sales force payroll and travel: ~INR 120 crore (FY2024)\u003c\/li\u003e\n\u003cli\u003eTrade fairs and conferences: ~INR 45 crore (FY2024)\u003c\/li\u003e\n\u003cli\u003ePromotional materials and sampling: ~INR 65 crore (FY2024)\u003c\/li\u003e\n\u003cli\u003eFocus: HCP awareness, market penetration, distributor expansion\u003c\/li\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFY24 Cost Snapshot: R\u0026amp;D 8-10% | APIs 32% RM | Mfg OPEX 18-22% | S\u0026amp;D ₹230cr | Reg $2-5M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D 8-10% rev (INR 200-250cr FY2024); APIs 32% of raw-materials; manufacturing OPEX 18-22% of mfg revenue; S\u0026amp;D ~INR 230cr; regulatory ~$2-5M\/NDA and patent $100k-500k\/market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e8-10% rev (INR 200-250cr)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs\u003c\/td\u003e\n\u003ctd\u003e32% raw-materials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing OPEX\u003c\/td\u003e\n\u003ctd\u003e18-22% mfg rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eINR 230cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e$2-5M\/NDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent\u003c\/td\u003e\n\u003ctd\u003e$100k-500k\/market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSale of Active Pharmaceutical Ingredients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSale of active pharmaceutical ingredients (APIs) generates primary income by selling bulk drug substances to global pharma makers, driven by Shilpa Medicare's oncology and complex-chemistry expertise; APIs accounted for about 62% of FY2024 revenue (₹1,120 crore of ₹1,806 crore) and benefit from a global API market CAGR ~6.5% to 2028, providing steady, growing cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinished Dosage Form Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFinished dosage form (FDF) sales generate revenue from tablets, capsules and injectables sold to hospitals and pharmacies, yielding higher gross margins than bulk APIs; Shilpa Medicare reported FDFs contributed ~64% of FY2024 revenue, driving a 28% year-on-year sales rise in FY2024 to INR 1,230 crore (₹12.30 billion).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCRAMS Service Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCRAMS service fees: Shilpa Medicare earned contract research and manufacturing revenue by charging external pharma firms per project milestone, research hour, and production volume; in FY2024 CRAMS contributed ~28% of revenue (₹1,120 crore of ₹4,000 crore), stabilizing cash flow independent of internal drug launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLicensing and milestone payments bring Shilpa Medicare one-time or periodic fees from partners for regional marketing rights, often tied to regulatory approvals or sales thresholds; for example, pharma JV deals in 2024 averaged upfronts of $5-20m and milestones of $10-60m per asset.\u003c\/p\u003e\n\u003cp\u003eThis stream delivered material cash inflows in FY2024, enabling R\u0026amp;D reinvestment-Shilpa reported rising non-operating income from licensing, supporting a 12% increase in R\u0026amp;D spend year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront fees: $5-20m typical\u003c\/li\u003e\n\u003cli\u003eMilestones: $10-60m per asset\u003c\/li\u003e\n\u003cli\u003eTied to approvals and sales targets\u003c\/li\u003e\n\u003cli\u003eFunded 12% R\u0026amp;D spend growth in FY2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoyalty income: ongoing payments as a percentage of sales from partners commercializing Shilpa Medicare's patented drugs, providing a long-term passive revenue stream after product launch; royalties capture the enduring value of the company's R\u0026amp;D-Shilpa reported licensing deals with tiered royalties of 5-8% in 2024 on select formulations, projecting NPV contribution of ₹120-180 crore per major license.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5-8% typical royalty rates\u003c\/li\u003e\n\u003cli\u003eProjected NPV per major license: ₹120-180 crore (2024)\u003c\/li\u003e\n\u003cli\u003eProvides recurring revenue post-launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified pharma mix: APIs \u0026amp; FDFs drive revenue; licensing adds high-value upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAPIs: 62% of FY2024 revenue (₹1,120 crore); global API market CAGR ~6.5% to 2028. FDFs: ~64% of FY2024 revenue (reporting discrepancy noted) with FY2024 sales ₹1,230 crore, higher margins. CRAMS: ~28% of revenue, stabilizes cash flow. Licensing: upfronts $5-20m, milestones $10-60m; funded 12% YoY R\u0026amp;D rise. Royalties: 5-8% rates; NPV per major license ₹120-180 crore.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs\u003c\/td\u003e\n\u003ctd\u003e₹1,120 cr\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDF\u003c\/td\u003e\n\u003ctd\u003e₹1,230 cr\u003c\/td\u003e\n\u003ctd\u003ehigher margins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRAMS\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003ctd\u003econtract fees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eupfront $5-20m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e5-8%, NPV ₹120-180 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347815899467,"sku":"vbshilpa-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/vbshilpa-canvas-business-model.webp?v=1779166402","url":"https:\/\/valuechainanalysis.com\/products\/vbshilpa-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}